Carvolix SA (EPA:CVX)

Market Cap	140.87M +157.6%
Revenue (ttm)	5.27M +306.6%
Net Income	-14.74M
EPS	-0.38
Shares Out	39.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,746
Average Volume	133,817
Open	3.630
Previous Close	3.580
Day's Range	3.440 - 3.740
52-Week Range	1.160 - 5.220
Beta	0.79
RSI	59.54
Earnings Date	Apr 24, 2026

About Carvolix

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 20...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 76
• Stock Exchange: Euronext Paris
• Ticker Symbol: CVX

Financial Performance

In 2024, Carvolix's revenue was 5.35 million, an increase of 337.09% compared to the previous year's 1.22 million. Losses were -14.74 million, -5.84% less than in 2023.